Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Muvalaplin · 1 trial · 2 indications
Time to first event in a MACE-4 composite endpoint, comprised of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, and urgent coronary revascularization.
| Arm | Type | Description |
|---|---|---|
| Muvalaplin | EXPERIMENTAL | Participants will receive muvalaplin orally. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo orally. |
| Name | Type | Description |
|---|---|---|
| Muvalaplin | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have Lp(a) ≥175 nanomoles per liter (nmol/L) * Meet one of the following criteria: * Have had a prior atherosclerotic cardiovascular disease (ASCVD) event (such as heart attack, stroke, or procedure to restore blood flow to the heart or other parts of the body) within 10 ye...
Muvalaplin is an investigational small molecule being developed for adults with elevated lipoprotein(a), or Lp(a), a condition linked to atherosclerotic cardiovascular disease. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
Muvalaplin is designed to lower elevated levels of lipoprotein(a), or Lp(a), a type of lipid associated with cardiovascular risk. It is being studied as a potential treatment to reduce major cardiovascular events in adults with elevated Lp(a) and atherosclerotic cardiovascular disease.
Muvalaplin is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting a Phase 3 clinical trial to evaluate the drug's effects on cardiovascular outcomes.
Muvalaplin is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 3 trial is recruiting participants to assess its impact on major cardiovascular events.
Muvalaplin is being studied in a Phase 3 trial with the identifier NCT07157774, titled 'Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a).' The trial is recruiting approximately 10,450 participants across multiple countries, including the United States, China, Japan, and European nations.
Muvalaplin is a distinct investigational small molecule developed by Eli Lilly and Company. It is not known to be the same as any other approved or marketed drug. It is being studied specifically for its effects on elevated lipoprotein(a) levels and cardiovascular outcomes.